TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2226079
Drug: Direct current
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct current therapy
Study: 389265
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus Bacille Calmette‐Guérin vaccine (BCG)
Study: 28917544
Drug: Pioglitazone (15-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15-45 mg)
Study: 28917544
Drug: Sulfonylureas (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylureas (5-15 mg glibenclamide, 2-6 mg glimepiride, or 30-120 mg gliclazide)
Study: 25775445
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 25 U of BoNT‐A to the masseter muscle bilaterally (Group I)
Study: 21746787
Drug: C+P (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: C+P (25 g carbohydrate + 10 g whey protein)
Study: 21746787
Drug: CHO (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (25 g carbohydrate)
Study: 16952635
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg tramadol/650 mg acetaminophen orally plus periprostatic 1% lidocaine
Study: 15252826
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/day for the first 4 weeks and 10 mg/day for the following 4 weeks)
Study: 11236074
Drug: Paroxetine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine and Sertraline
Study: 8420311
Drug: Transdermally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermally administered 17 beta‐estradiol
Study: 3736737
Drug: Ibopamine, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine, 200 mg and 600 mg
Study: 3736737
Drug: Indoramin, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin, 50 mg
Study: 27098150
Drug: Trastuzumab/Lapatinib combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab/Lapatinib combination
Study: 26238121
Drug: Roxadustat 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat 0.7 mg/kg BIW
Study: 26238121
Drug: Roxadustat 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat 1.0 mg/kg BIW
Study: 26238121
Drug: Roxadustat 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat 1.5 mg/kg BIW
Study: 26238121
Drug: Roxadustat 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat 2.0 mg/kg BIW
Study: 26238121
Drug: Roxadustat 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat 2.0 mg/kg TIW
Study: 21123458
Drug: 1100 mg
Normalized name: mineral oil 1100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1100 mg choline/d
Study: 9088581
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg sotalol alone (phase 1)
Study: 9088581
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg sotalol plus 20 ml of antacid (phase 2)
Study: 9088581
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg sotalol plus antacid given 2 h after sotalol (phase 3)
Study: 9088581
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of sotalol and MAH
Study: 1441789
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg recombinant human SOD (rh-SOD) administered intravenously 10-20 minutes prior to reperfusion
Study: 23651789
Drug: Topical diacerein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diacerein 1%
Study: 17947606
Drug: rhGH +
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH + parenteral nutrition (PN)
Study: 17947606
Drug: parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: parenteral nutrition (PN)
Study: 3122554
Drug: Milk-based food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-based food supplement
Study: 3122554
Drug: Milk-based food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-based food supplement plus breakfast meal
Study: 3122554
Drug: Lactose solution
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose solution (control)
Study: 20196640
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) - estradiol and progestogen
Study: 19904267
Drug: Gemcitabine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (900 mg m(‐2) over 30 min), oxaliplatin (65 mg m(‐2)), and 5‐FU (1500 mg m(‐2) over 24 h) on days 1 and 8 of a 21‐day cycle
Study: 19904267
Drug: Gemcitabine, oxaliplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine, oxaliplatin, and 5‐FU chemotherapy
Study: 16761242
Drug: Travoprost 0.004%/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost 0.004%/timolol 0.5% ophthalmic solution in the morning
Study: 16761242
Drug: Travoprost 0.004%/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost 0.004%/timolol 0.5% ophthalmic solution in the evening
Study: 11430537
Drug: Neostigmine 0.4-0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.4-0.8 mg/h over 24 h
Study: 8122736
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic solution at body temperature (37 +/- 1 degrees C)
Study: 8122736
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic solution at room temperature (22 +/- 1 degrees C)
Study: 24550219
Drug: Short-term intensive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term intensive insulin therapy (IIT) consisting of basal insulin detemir and premeal insulin aspart for 4 weeks
Study: 24550219
Drug: Short-term intensive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term intensive insulin therapy (IIT)
Study: 18605232
Drug: Daonil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daonil (10 mg glyburide)
Study: 18605232
Drug: Gen-Glybe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gen-Glybe (10 mg glyburide)
Study: 15360941
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of textbook and CAI (CP)
Study: 23139359
Drug: 80 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/d atorvastatin
Study: 9227718
Drug: Pranlukast 337.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast 337.5 mg twice daily
Study: 9227718
Drug: Pranlukast 225
Normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pranlukast 225 mg twice daily
Study: 9227718
Drug: Pranlukast (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (both doses)
Study: 8424425
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg tid
Study: 8424425
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg qid
Study: 8424425
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg hs
Study: 3317345
Drug: Recombinant yeast-derived
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant yeast-derived hepatitis B vaccine (2.5, 5, 10, or 20 micrograms)
Study: 3317345
Drug: Recombinant yeast-derived
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant yeast-derived hepatitis B vaccine (20 micrograms booster)
Study: 3317346
Drug: Plasma-derived hepatitis
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived hepatitis B vaccine (20 micrograms)
Study: 28846481
Drug: HA and
Normalized name: rAAV2/1 Hex alpha and beta
DrugBank: CAM-GM201 (DB17687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA and Liposic EDO Gel (Group 2)
Study: 28846481
Drug: HA, DQS,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA, DQS, and Liposic EDO Gel (Group 3)
Study: 25533398
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of histone deacetylases (HDACi)
Study: 22139545
Drug: Oral Fructus
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Fructus bruceae oil (20 mL, 3 times per day for 12 weeks) combined with radiotherapy (60‐65 Gy, 6‐7 weeks)
Study: 19469786
Drug: PGE₁‐EE (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE₁‐EE (maximum 1000 μg) applied transdermally using an adhesive foil patch
Study: 19469786
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 μg PGE₁‐EE)
Study: 22228413
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser treatment
Study: 28095541
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with pulsed dye laser and CO2 ablative fractional resurfacing
Study: 15478785
Drug: Trager treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trager treatment group
Study: 11875895
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in a rehabilitation centre in Tenerife for four weeks
Study: 11875895
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in two similar centres in Norway for four weeks
Study: 8179148
Drug: Crystalloid priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crystalloid priming solution
Study: 8179148
Drug: Colloid priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid priming solution
Study: 3117566
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of triglyceride emulsions (LCT; MCT/LCT)
Study: 29273467
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil capsules (Colpermin)
Study: 16965866
Drug: Hypofractionated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiation therapy (55 Gy/20 fractions/4 weeks)
Study: 16965866
Drug: Conventional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional radiation therapy (64 Gy/32 fractions/6.5 weeks)
Study: 14756266
Drug: Daclizumab 1
Normalized name: daclizumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 1 mg/kg
Study: 10777469
Drug: New chemotherapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New chemotherapeutic agents (paclitaxel, docetaxel, vinorelbine, gemcitabine, irinotecan)
Study: 20697547
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy regimens
Study: 10777469
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and cisplatin-based combination regimens
Study: 1313340
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin by continuous intravenous infusion
Study: 29152672
Drug: Original G-CSFs
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original G-CSFs (lenograstim and pegfilgrastim)
Study: 23460503
Drug: Fesoterodine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine (4 mg, with potential increase to 8 mg after 4 or 8 weeks)
Study: 23460503
Drug: Fesoterodine (double-blind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine (double-blind treatment)
Study: 23460503
Drug: Placebo (double-blind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (double-blind treatment)
Study: 22238574
Drug: TAU+FT (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU+FT (Treatment as Usual plus Family Therapy)
Study: 11314873
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg citalopram orally 2 hours before ECT
Study: 9006785
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (500 mg) with standard breakfast
Study: 9006785
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (500 mg) with cholecystokinin (0.3 micrograms/kg)
Study: 9006785
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (500 mg) under fasting conditions
Study: 1428302
Drug: Isradipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (10 mg single dose)
Study: 1428302
Drug: Slow-release nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release nicardipine (40 mg twice daily for six months)
Study: 11390120
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 1 mg/day
Study: 11390121
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 2 mg/day
Study: 8424908
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent cisplatinum
Study: 3596167
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg) intravenously before tests
Study: 3596167
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg q.i.d., p.o.) for 1 month
Study: 3187
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oxytetracycline a day p.o. for 6 weeks after initial treatment with 1 g oxytetracycline a day p.o. for 1 week
Study: 3187
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 100 mg oxytetracycline and 1.2 g sodiumbituminosulfonates a day p.o. for 6 weeks after initial treatment with 1 g oxytetracycline a day p.o. for 1 week
Study: 3187
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oxytetracycline a day p.o. for 6 weeks after treatment with combination therapy
Study: 29149776
Drug: Nebulized 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized 2.5 mg of salbutamol and 2.5 mL of 3% hypertonic saline solution for three consecutive 20-min periods
Study: 29149776
Drug: Nebulized only
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized only salbutamol in the same dose and time as the intervention group
Study: 26068515
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (12 sessions within 48 hours of injury)
Study: 21813427
Drug: Risperidone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (up to 4 mg once daily)
Study: 16765589
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil)
Study: 11378343
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy with additional radiotherapy or tamoxifen
Study: 3101849
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplements (200,000 IU orally immediately and again the next day)
Study: 3101849
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplements (200,000 IU orally immediately and again the next day) in children aged under 2 years
Study: 3101849
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment alone (Control) in children aged under 2 years
Study: 23720411
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose load (75 grams of carbohydrates in 300 mL water)
Study: 23720411
Drug: Water (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (300 mL)
Study: 20580111
Drug: IMRT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT treatment with dose of the day assessment
Study: 16621327
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of somatostatin to block GH secretion during the first 3 hours of sleep (mainly SWS)
Study: 12691793
Drug: Quetiapine 25‐75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 25‐75 mg/day
Study: 11205648
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg, 40 mg, and 20 mg in 2-week intervals for 6 weeks)
Study: 11205648
Drug: Prednisone (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (during steroid treatment)
Study: 11205648
Drug: Placebo (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (during steroid treatment)
Study: 9247506
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR 2.0 to 2.5) plus aspirin (150 mg daily)
Study: 9247506
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin (150 mg daily)
Study: 8233735
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of Curosurf (200 mg/kg body weight)
Study: 8233735
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of Curosurf
Study: 3303425
Drug: Betamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (8 mg) administered intramuscularly for 10 days
Study: 3303425
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg) administered orally for 10 days
Study: 3303425
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections and tablets
Study: 30412448
Drug: Abicipar 1
Normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abicipar 1 mg
Study: 30412448
Drug: Abicipar 2
Normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abicipar 2 mg
Study: 22109762
Drug: Alprazolam plus
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam plus four intratympanic dexamethasone (ITD) injections
Study: 22109762
Drug: Alprazolam plus
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam plus four ITD injections plus four intravenous injections of lipo-prostaglandin E(1)
Study: 16415095
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate 100 mg/day
Study: 1845926
Drug: No beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blocker (control)
Study: 1377245
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of gentamicin and metronidazole
Study: 1377245
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of gentamicin and metronidazole
Study: 6462404
Drug: Dexamethasone (steroid)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (steroid) administration during and after lumbar discectomy
Study: 31477280
Drug: 22 unique
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [UNIQUE Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 unique antibodies (survival-associated antibodies, SAAs) used to stratify patients into low-, medium-, or high-risk survival groups.
Study: 29801482
Drug: Mwanamphepo (herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mwanamphepo (herbal medicine)
Study: 23145756
Drug: Augmentation technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation technique with hamstring tendon autograft
Study: 20708814
Drug: Sitagliptin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin administration
Study: 15812753
Drug: Sequential biventricular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential biventricular pacing
Study: 785608
Drug: Aspirin-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-Placebo
Study: 30509271
Drug: Empagliflozin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (25 mg daily)
Study: 31390907
Drug: Pitavastatin Monotherapy
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin Monotherapy
Study: 11057103
Drug: RANTES concentrations
Normalized name: Rantec
Approvals — FDA: no, EMA: no, PMDA: no
Description: RANTES concentrations in BALF from s.A (14.4 pg/ml)
Study: 11057103
Drug: RANTES concentrations
Normalized name: Rantec
Approvals — FDA: no, EMA: no, PMDA: no
Description: RANTES concentrations in BALF from s.B (10.9 pg/ml)
Study: 7586312
Drug: Intravenous bretylium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bretylium (4.7 g)
Study: 7586312
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (high dose: 1.8 g)
Study: 7586312
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (low dose: 0.2 g)
Study: 86040
Drug: String capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: String capsule for duodenal specimen collection
Study: 28878048
Drug: Interventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional therapy (IT)
Study: 23833361
Drug: Agaricus sylvaticus
Normalized name: AGARICUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agaricus sylvaticus supplementation (2.1 g/day)
Study: 21843336
Drug: Dry cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry cupping treatment (5 sessions over 2 weeks)
Study: 17454712
Drug: Cessation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation treatment delivered within a randomized clinical trial
Study: 9753485
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 9 mg once daily for 8 weeks